Protagonist Therapeutics (PTGX) Selects Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications

Go back to Protagonist Therapeutics (PTGX) Selects Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications
(NASDAQ: PTGX) Delayed: 8.90 +0.59 (7.10%)
Previous Close $8.31    52 Week High $24.52 
Open $8.35    52 Week Low $10.02 
Day High $8.90    P/E N/A 
Day Low $8.21    EPS $0.00 
Volume 713,764